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South Africa has one of the highest Human 
Immunodeficiency Virus (HIV) prevalence rates at 
12.2% in 2012 of which 14.4% were female.(1)   The 
Joint United Nations Programme on 
HIV/AIDS(UNAIDS) 2014 Gap Report confirmed the 
epidemic in Sub-Saharan Africa and reported one in 
every four new HIV infections to occur in adolescent 
and young females.(2) 
Unsurprisingly the wellbeing of these women and 
their unborn children has become key in the global 
fight against HIV/AIDS.  The World Health 
Organisation (WHO) has supported this by 
advocating elimination of new paediatric HIV 
infections and keeping mothers alive by 2015.(3) 
Several challenges threaten the success of PMTCT in 
developing countries.  In Malawi, high HIV 
prevalence rates complicated by factors such as 
short birth intervals and late antenatal bookings 
decreased the effectiveness of the program.(7)  In 
addition insufficient laboratory resources in many 
centres cause delayed CD4 testing, unnecessary 
deferral of ART initiation and consequently higher 
risk of MTCT and maternal morbidity and 
mortality.(7) 
Attempting to improve access to and uptake of 
patients in ART care Malawi launched ‘Option B+’ as 
pilot program in 2011, rolling out rapid testing and 
same day lifelong ART initiation for all HIV positive 
pregnant and breastfeeding women.(7)  Concerns 
around long term feasibility of the regimen 
surfaced,(8) but largely positive outcomes ultimately 
led to updated WHO ART guidelines in 2012.(9) 
Experiencing similar challenges to Malawi South 
Africa implemented revised ART guidelines in April 
2013 with the Western Cape following Malawi’s suit 
with ‘Option B+’.(10) 
Unsurprisingly concerns regarding patient retention 
on ‘Option B+’ have surfaced.  Hypotheses propose 
attrition peaks at ART initiation and postpartum 
after cessation of breastfeeding with different 
suggestions of possible contributing factors.(11) 
Considering the valid concerns around ‘Option B+’ 
on the background of evident positive outcomes 
and the lack of local evidence further research is 
imperative.  While positive outcomes will affirm the 
value of ‘Option B+’ the results of this study will 
contribute to development of retention strategies 
and decisions around regimen choices for individual 
provinces. 
Study title 
The retention in care of HIV positive pregnant and 
breastfeeding patients universally initiated on 
lifelong ART (‘OptionB+’) in the Klipfontein/Mitchells 
Plain substructure in Cape Town. 
 
 
Literature Review (Extensive literature review in Part B) 
Reducing vertical transmission 
Before the introduction of PMTCT programs the HIV 
infection rate amongst breastfed infants in 
developing countries was estimated as high as 25% - 
35% in the first 6 months.(15) 
Literature searches on HIV PMTCT revealed a lack of 
international data with the majority originating 
from Sub-Saharan Africa.  One of the most 
significant, the Kesho Bora study, was conducted in 
Burkina Faso, Kenya and South Africa between 2005 
and 2008.(12)  This randomised control trial 
compared HIV MTCT in breastfeeding mothers on 
triple ART to that in breastfeeding mothers on AZT 
and single dose nevirapine prophylaxis.(12) 
 
The outcomes of this trial changed the face of 
PMTCT and global views on HIV exposed infant 
feeding practices.  It showed a 43% relative risk 
reduction in infant HIV infection at 12 months in the 
triple ART group with no significant difference 
between the two groups at birth or 6 weeks 
postpartum.(12)  Similar outcomes were 
demonstrated looking at feeding practices with a 
relative risk reduction in HIV transmission of 48% in 
the triple ART group compared to the AZT/single 
dose nevirapine group.(12) 
 
With results this significant it is important to 
confirm validity of the results.  Including five study 
sites across three countries, having a large study 
population and conducting a randomised control 
trial improved study outcomes’ significance.(12)  
Authors were transparent with the selection process 
and follow up not concealing confounding factors or 
difficulties encountered.(12) 
 
The study’s most relevant publications, the MTCT 
and breastfeeding results, were transparent and 
appropriately used odds ratios and relative risk 
reduction.  Confidence intervals and p-values aided 
in interpreting statistical significance of results and 
thus relevance in clinical practice.(12) 
 
These controversial but indisputable results 
significantly impacted the future of HIV PMTCT.  
With clear evidence that ART in pregnancy and 
breastfeeding decreases HIV MTCT the WHO revised 
its guidelines to include these new findings.(5) 
 
Retention is key 
Adherence is vital in all patients on ART, but 
especially in HIV positive pregnant and 
breastfeeding women to preserve maternal health, 
reduce drug resistance and prevent HIV MTCT.(16)  
Studies have shown that adherence rates as low as 
70–80 % sufficiently suppress the virus(16), but they 
emphasize much more favourable outcomes with 
better adherence.  In pregnant and breastfeeding 
women this is particularly essential to ensure the 
lowest possible risk of MTCT and to aim to eliminate 
new vertical HIV infections by 2015.(3) 
In a systematic review of ART adherence during 
pregnancy and breastfeeding compiled in 2012, 
collective international data showed a statistically 
significant higher retention rate of 75.7% in the 
antepartum period compared to a mere 53% in the  
postpartum period (p=0.005).(16) 
It is evident that patient retention in ART care prior 
to ‘Option B+’ was suboptimal with adherence rates 
below even the lowest acceptable rate to achieve 
viral suppression.  In addition, adherence during 
pregnancy seems superior to the postpartum 
period, most likely due to mothers’ instinctive 
motivation to protect their unborn child with 
external pressures influencing their behaviour after 
delivery.(16) 
Nonetheless, ‘Option B+’ continued to raise 
questions.  While it markedly increases ART 
accessibility and availability(7) it demands patient 
dedication and capacity to adhere to the regimen.  
Only with successful combination of these factors 
can the goal to eliminate HIV MTCT be fully 
achieved.(16) 
Research on ART patient retention during 
pregnancy, prior to roll-out of the 2012 WHO ART 
Guidelines, were conducted in Johannesburg in 
2010.(17)  This retrospective cohort study revealed 
much higher attrition rates in patients initiated on 
‘Option A’ compared to patients eligible for triple 
ART.(17)  Only 40.3% of ‘Option A’ patients were 
retained during antenatal care with a mere 22.6% 
returning for the required repeat CD4 count after 
delivery.(17)  Antenatal retention of ART eligible 
patients was higher at 48.9% with a further 8.4% 
LTFU six months postpartum, still suboptimal 
compared to international data.(17) 
Recognising the need for improved patient 
retention and identifying compounding factors in 
developing countries contributed to the 
development of the current WHO ART Guidelines 
and ,in certain settings ,’Option B+’. 
A pilot study conducted in Cape Town in 2011 
implemented `‘Option B+’ principles similar to the 
Malawian guidelines at the time(7) and ultimately 
every HIV positive pregnant patient received triple 
ART regardless of CD4 count or WHO staging.(4)  
Results revealed remarkable ART initiation of 91% at 
first antenatal booking visit with longer antenatal 
ART exposure and consequently complete viral load 
suppression at delivery in 75.8% of patients and a 
negligible vertical transmission rate of 0.9%.(4) 
The success of rapid ART initiation demonstrated by 
this and other studies further supported the 
international shift to ‘Option B/Option B+’ with 
undoubted benefits to both mother and baby.(4, 7, 18)  
In appropriate settings, specifically developing 
countries, this simplified algorithm seemed the long 
awaited solution to major obstacles and the 
publication of revised international guidelines only a 
matter of time. 
The birth of ‘Option B+’ 
It has now widely been accepted that ART improves 
maternal HIV viral load suppression and 
consequently leads to improved HIV PMTCT.(4)  
Despite widely implemented ART regimens such as 
‘Option A’ several factors (especially in Sub-Saharan 
countries) serve as potential barriers to early and 
rapid initiation. 
Malawi identified this problem early on, and 
proposed ‘Option B+’ as a feasible alternative 
regimen.(18)  In a 2011 Lancet article, Schouten et al 
discuss the motivation behind this decision, and 
identify difficult access to CD4 testing, high fertility 
rates, late antenatal bookings and extended 
breastfeeding as major barriers to ART initiation.(19)  
The article supports ‘Option B+’s’ intended 
treatment protocol and identifies ‘Option B+’s’ 
strengths as its early defined treatment goals and 
improved patient recruitment.(19) 
The Malawian Ministry of Health (MOH) 
implemented ‘Option B+’ in 2011 with promising 
expectations of decreased morbidity, mortality and 
better PMTCT.(18)  Indeed, initial routine monitoring 
by the MOH showed positive outcomes with a seven 
fold increase in PMTCT coverage during the first 
year and retention at 6 months of 82,6% and 76,9% 
at 12 months.(7)  These results sparked global 
interest, as they made the proposed 
UNAIDS/PEPFAR (Presidents emergency plan for 
AIDS relief) goal of eliminating new HIV infections in 
children by 2015 all the more attainable.(3)  
Developing countries facing PMTCT challenges 
similar to those in Malawi now had the potential to 
show equally promising outcomes, and soon 
Uganda, Rwanda and Haiti adopted ‘Option B+’ into 
their PMTCT policies.(18) 
Nevertheless, despite 12 month retention rates 
comparable to those prior to implementing ‘Option 
B+’, questions regarding lifelong retention of 
patients surfaced.(18)  Considering that patients on 
this regimen often have high CD4 counts and no 
Stage 3 or 4 defining illnesses, risk of LTFU after 
cessation of breastfeeding became a growing 
concern.(18) 
Twelve months after the introduction of ‘Option B+’ 
the MOH conducted a more extensive study and the 
results were published in AIDS Journal in 2014.(7)  
This study consisted of two study arms, the first 
exploring selected facilities’ patient retention in 
care (factoring possible site-level predictors of 
patient LTFU)  and the second determining LTFU in 
pregnant and breastfeeding women on ‘Option B+’ 
compared to non-pregnant women starting ART for 
their own health.(7) 
Results reflected previous programmatic data on 
‘Option B+’, with similar LTFU rates of 17% and 22% 
at 6 and 12 months after ART initiation 
respectively.(7)  Additionally outcomes showed 
women initiating ART during pregnancy to be five 
times more likely to become LTFU compared to non-
pregnant women.(7)  Patients initiated during 
breastfeeding had the highest attrition risk at twice 
that of pregnant ART starters.(7)  Large numbers of 
study participants, the inclusion of multiple sites, 
including both facility level and individual data in 
separate study arms all added to improve 
generalisation of findings. 
Unsurprisingly, Malawi’s pilot project sparked 
controversy, with Coutsoudis et al. criticising ‘Option 
B+’ in a Lancet 2013 publication and a debating 
editorial comment in AIDS Journal in 2014.(8, 20)  
While the editorial questions the feasibility of 
‘Option B+’, it maintains a balanced appraisal and 
encourages further research.(20)  Instead Coutsoudis 
et al. label ‘Option B+’ as “extreme”, criticise 
Malawi’s “test and treat” approach and warn about 
pressure on countries to adopt the new regimen.(8)  
This criticism seems biased as the authors do not 
engage with the several positive and negative 
aspects of this issue.  In a subsequent Lancet 
correspondence the WHO dismisses the criticism 
and supports the generally accepted positive but 
cautionary view on ‘Option B+’ encouraging further 
research on the matter.(20) 
In 2012 the WHO incorporated ‘Option B+’ into the 
revised PMTCT Guidelines providing much needed 
confidence for further roll out whilst continuing to 
provide alternative regimen options to settings 
which found it less viable.(9) 
Subsequently, South African National ART 
Guidelines were revised in 2013 with national 
implementation in April 2013.(10)  These guidelines 
advocate ‘Option B’ in pregnant HIV positive women 
with the Western Cape Department of Health 
opting for ‘Option B+’ as part of their provincial 
guidelines.(10) 
One year after implementation of ‘Option B+ in the 
Western Cape, important questions remain 
unanswered.  Despite successes with increased 
access and availability of ART, growing concerns 
regarding long term retention exist. 
The proposed study aims is to appreciate the 
attrition rate in the Hanover Park/Mitchells Plain 
ART community and to better understand the 
challenges faced.  Recommendations and suggested 
interventions to promote retention can then then 
be made.  Optimistically, this study will prompt 
further research, influence policy development and 
ultimately add value to both national and 
international PMTCT knowledge. 
Aims 
1) To determine the retention in care of HIV 
positive pregnant and breastfeeding women 
universally initiated on lifelong ART (‘Option B+’) at 
Hanover Park Community Health Centre (CHC) and 
Mitchells Plain Community Health Centre (CHC) in 
the Klipfontein/Mitchells Plain substructure in Cape 
Town. 
2) To compare retention in care of pregnant 
and breastfeeding women initiated on ART using 
‘Option B+’ to HIV positive women initiated on ART 
because of their own health (i.e. CD4 
count<350cells/ul or WHO stage 3 or 4). 
Objectives 
1) To identify all HIV positive and ART naïve 
pregnant women initiated on ART using ‘Option B+’ 
at Hanover Park CHC and Mitchells Plain CHC 
between April 2013 and Aug 2013. 
2) As a control identify non-pregnant, ART 
naive HIV positive women initiated on ART with a 
CD4 count<350cells/ul or WHO stage 3 or 4 at 
Hanover Park CHC and Mitchells Plain CHC between 
April 2013 and Aug 2013. 
3) To compare the retention rate of patients in 
the pregnant group to that in the non-pregnant 
group at 1, 3, 6, 12 and 15 months post initiation of 
ART. 
4) To conclude what impact ‘Option B+’ 
implementation has had on patient retention in ART 
care in the Hanover Park/Mitchells Plain 
communities. 
5) To explore possible determinants of LTFU in 
patients initiated on ‘Option B+’ in the Hanover 
Park/Mitchells Plain communities. 
6) To make recommendations to optimise 




Retrospective cohort study. 
Study Site(s) 
The Western Cape Primary Health Care model 
includes 479 facilities in 6 districts (5 rural and 1 
metro).  The Cape Town metro district consists of 
four sub-structures. 
ART services in the Western Cape have mostly been 
decentralised with most patients receiving care at 
primary care level.  Primary level ART care is based 
on a nurse driven service model with doctor 
support aiming to increase accessibility. 
Successful integration of antenatal and PMTCT 
services has been implemented across the province.  
Most pregnant and breastfeeding HIV positive 
patients attend one site for ART, antenatal and 
postnatal care simplifying management and 
improving continuity of care.  Advantages include 
increased patient centeredness and better resource 
allocation. 
At both facilities pregnant women are initiated on 
ART at the onsite MOU and follow up continued at 
the onsite ART clinic.  ART initiation and follow up of 
non-pregnant patients take place at the same 
facilities’ ART clinics. 
Hanover Park CHC 
This 24 hour facility is located on Hamlyn Walk in 
Hanover Park, Cape Town and forms part of the 
Klipfontein/Mitchells Plain substructure.  It provides 
primary health care, 24 hour accident and 
emergency services, midwifery and has an ART 
Clinic on site.  The unit works closely with the onsite 
MOU serving a large population of pregnant and 
breastfeeding women living with HIV. 
Mitchells Plain CHC 
This 24 hour facility is located on First Avenue in 
Eastridge, Mitchells Plain, Cape Town.  It also forms 
part of the Klipfontein/Mitchells Plain substructure 
serving a similar patient population profile to 
Hanover Park CHC. 
Services offered at Mitchells Plain CHC are 
comparable to those described at Hanover Park CHC 
and the working relationship between the ART clinic 
and MOU is based on the same model. 
Study site selection 
The study would be best conducted at a primary 
health care centre that has an onsite MOU as well 
as integrated ART services.  The ART clinic should 
have implemented ‘Option B+’ from April 2013 in 
order to be included in this study.  Sites using 
electronic record keeping systems (ERKS) is 
preferable (although not considered an exclusion 
criteria) due to the accessibility and probable 
accuracy of patient information. 
Several CHC’s in the Cape Town metro have both an 
MOU and ART clinic offering integrated services.  To 
the researchers’ knowledge all sites providing ART 
care in the Western Cape rolled out ‘Option B+’ in 
April 2013 with very few, if any exceptions. 
Record keeping and data capturing vary between 
sites ranging from paper-based records to 
sophisticated ERKS depending on availability and 
suitability. 
Hanover Park and Mitchells Plain CHC were selected 
on the basis of convenience.  The principal 
researcher is based at Hanover Park CHC for the 
majority of the study period simplifying the data 
collection process.  In addition, having both the 
principal investigator and co-supervisor 
permanently based at the facility made it the most 
practical option.  Both Hanover Park and Mitchells 
Plain CHC are located within the 
Klipfontein/Mitchells Plain substructure serving a 
similar patient profile with comparable clinical 
challenges. 
Participants 
Participants will be assigned to two cohort groups 
based on the pre-specified selection criteria. 
The control group will consist of HIV positive, non-
pregnant, female patients initiated on ART at 
Hanover Park and Mitchells Plain ART Clinics during 
the specified period.  Owing to current ART 
guidelines participants should have a CD4 
count<350cells/ųl or be WHO stage 3 or 4 at ART 
initiation. 
The cohort group will include pregnant patients that 
booked at Hanover Park and Mitchells Plain MOU 
during the specified period.  Only women testing 
HIV positive and that are ART naïve at antenatal 
booking will be included in the study.  In accordance 
with ‘Option B+’ guidelines, patients in this group 
could have any CD4 count or WHO clinical stage at 
initiation. 
Participants will not be excluded based on other 
demographic characteristics.  However, during data 
analysis, multivariate logistics regression will be 
used to account for any confounding variables. 
Participant sampling 
Patient sampling will start by accessing MOU ACTS 
(Advise, Counsel, Test, Support) registers at the two 
included sites.  These registers document each 
antenatal patient’s HIV rapid test result, making it 
ideal data sources.  However, like all registers, they 
are paper based and depend on individual 
counsellor vigilance and accuracy, which is variable. 
As an additional data source, each facility’s ERKS will 
be utilised.  Hanover Park ART clinic makes use of 
Tier.net whilst Mitchells Plain ART clinic stores 
patient data on Ekapa. 
Basic operation of both sites’ ERKS is similar with 
user friendly interfaces simplifying data retrieval.  
Another advantage of this data collection method is 
accuracy as each clinical visit is captured on the 
system daily. Both sites’ ERKS allow criteria selection 
to filter data and produce a patient sample.  
Sampling the cohort group will use “pregnant at 
ART start” and “April 2013 – Aug 2013” as filters.  
Participants in the control group will be selected 
using “female” and “non-pregnant” as filters within 
the same period as the cohort group. 
Sample sizes are projected as 200 cohort group 
participants with 400 included in the control group.  
Sample sizes are based on programmatic data 
obtained from the Hanover Park ART administrative 
clerk and are mere estimations.  Should patient 
sampling reveal more participants meeting the 
inclusion criteria or produce less patients in either 
group sample sizes may be affected. 
Data Collection 
Data collection will be conducted primarily by the 
principal researcher. 
The MOU ACTS registers will be primarily used to 
identify all pregnant patients that tested HIV 
positive at the MOU during the specified time 
period and to capture each included participant’s 
demographic data using the data collection tool. 
(See Part D) 
Ekapa and Tier.net will be accessed to determine 
participant retention as either “Yes” or “No” at the 
first visit and 1, 3, 6, 9, 12 and 15 months post ART 
initiation in the respective groups.  “First visit” will 
refer to a patient’s first subsequent visit to the ART 
Clinic after initiation of ART. 
Using these crucial points in care to determine 
patient retention researchers will be able to identify 
both patients “never returning for follow up” and 
those “lost to follow up”.  We define “never 
returning for follow up” as a patient not returning 
for ART care after their initial visit.  This becomes 
especially important in the cohort group in which 
the MOU initiate pregnant HIV positive women on 
ART at their booking visit with continued follow up 
at the ART clinic.  Patients will be classified as LTFU 
should they not attend ART care for 90 days or 
longer after their last ART clinic visit.  The 
researchers base these definitions on current 
standard of practice (SOP) at the study sites as well 
as a review of existing studies.(7, 14)   To account for 
reasons other than true attrition additional 
outcomes will be added such as “transfer out” and 
“death”. 
Relevant patient demographic data will be collected 
using the same data collection tool.  This will 
include age, divided into four subcategories, 
employment status, marital status, residing suburb, 
baseline CD4 count, WHO clinical stage and their 
counselling rate prior to initiation.  The researchers 
hypothesise that these factors potentially 
contribute to patient retention and will discuss its 
relevance in the final report. 
The investigators recognise the possibility of 
insufficient electronic patient data in which case 
individual patient folders will be accessed to obtain 
the required information. 
Data Collection Tool (See Part D) 
Collection of data will be done using a pre-
programmed Excel spread sheet.  Data will be 
captured directly onto the spread sheet by the 
principal researcher throughout the data collection 
process. 
Data Analysis 
The raw data collected will be entered into a 
biomedical statistics program such as BioStrata to 
compare retention rates between the two groups 
using odds ratios.  Logistic regression will be used to 
account for possible confounding variables. 
We are projecting to recruit 200 experimental 
subjects and 400 control subjects.  Prior data 
indicates that the retention rate among controls is 
0.83.  We will be able to detect true retention rates 
of 0.727 or 0.916 in exposed subjects with 
probability (power) of 0.8.  The Type I error 
probability associated with this test of the null 
hypothesis that the failure rates for experimental 
and control subjects are equal is 0.05.  We will use a 
continuity-corrected chi-squared statistic or Fisher’s 
exact test to evaluate this null hypothesis. 
The projected statistical analysis is based on a 
review of the current available literature.  The 
expected retention rate of 0.83 is derived from the 
recently conducted Malawian study owing to its 
relevance and actuality.(7)  Should more appropriate 
literature become available during data analysis or 
the number of study participants change due to 
unforeseen circumstances this might influence the 
projected detectable retention rates as outlined 
above.  In this instance the investigators will clearly 
outline and discuss the reasons and impact it will 
have in the final document. 
Ethical Considerations 
Application for ethics approval will be submitted to 
both the Human Research Ethics Committee of the 
Faculty of Health Sciences of the University of Cape 
Town (UCT) and the Department of Family Medicine 
Research Committee. 
 
Considering the retrospective study design 
exclusively involving accessing patient records 
without direct patient interaction individual 
informed consent will be difficult to acquire.  Since 
data is in the care of the facilities and remains the 
property of the Western Cape Department of 
Health, consent to gain access to patient 
information will be obtained from the facility 
managers. (See Part D)  They will act as custodians of 
the folders, but as proxy representatives of the 
patients. 
 
The data collection process is outlined above.  
Expected duration of data collection is projected at 
thirty days up to a maximum of ninety days in the 
event of encountering unforeseen circumstances. 
 
Confidentiality of patient information will be 
maintained with patient identification done only 
through folder numbers.  Should a patient’s folder 
need to be accessed for information the patient’s 
identity will be kept confidential and only known to 
the researcher responsible for data collection.  In 
addition only patient information required to 
conduct the study will be collected, particularly with 
regards to patients’ personal data to ensure optimal 
patient privacy. 
Collected data will be stored electronically in the 
care of the principal researcher and stored 
anonymously protecting misuse by a third party.  
Collected data will be stored for 5 years from 
completion of the study to allow for perusal or 
inclusion in future studies with permission from the 
principal investigator and facility managers of the 
included study sites. 
Results will be kept confidential and if published 
patient identity will remain anonymous. 
 
No monetary incentives, compensation or payment 
in kind will be offered to either study participants or 
facilities involved.  The investigators have no 
conflicts of interest to declare. 
On conclusion of the study, results will be 
disseminated to the facility managers involved as 
well as to the ARV/Wellness Clinic managers of each 
facility.  The results will be included in the proposed 
Masters dissertation of the principle researcher and 
submitted for grading to the UCT Department of 
Family Medicine and the College of Medicine South 
Africa.  Study results will be made available to 
interested governing bodies to promote further 
interest in the study field and make 
recommendations to positively impact future 




Funding to conduct the research will be applied to through the University of Cape Town School of Public Health 




Activity Amount (ZAR) Description 
Equipment & 
Consumables 
Printing R300 Letters of permission, 
Proposal documents, 
Application Forms, 
Data Collection Sheets 
 Telephone R200 R100/month x 2 
months 
 Transport R300 R3/km (AA rates) x 
100km 
Human Resources Proofreading R1000 R10/page x 100 pages 
 Biostatistician R200 R50/hour x 4 hours 
Final Report Printing & Binding R1000 Printing & Binding for 
dissemination & 
submission 
Other Presentation of results 
at conference 
R1000 Conference enrolment 
fee 
    
Total cost 
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 Option A recommends zidovudine (AZT) to 
all human immunodeficiency virus (HIV) 
positive pregnant and breastfeeding 
women not qualifying for lifelong triple 
antiretroviral treatment (ART) from 14 
weeks gestation with single dose 
nevirapine and tenofovir/emtracitibine 3 
hourly in labour. 
 Option B recommends universal ART to all 
HIV positive pregnant and breastfeeding 
women.  Patients with CD4 counts less 
than 350 cells/ųl or at World Health 
Organisation (WHO) stage 3 or 4 continue 
ART lifelong while those not meeting these 
criteria discontinue ART one week after 
cessation of breastfeeding. 
 Option B + recommends lifelong ART to all 
pregnant and breastfeeding HIV positive 
women regardless of CD4 count or WHO 
clinical staging. 
b) Objectives 
 To identify current published literature on 
the prevention of mother to child 
transmission (PMTCT) of HIV among 
pregnant and breastfeeding women, 
retention in long term ART care and 
‘Option B+’. 
 To select literature relevant to the 
proposed research project by applying 
defined inclusion criteria. 
 To critically appraise selected literature 
using evidence based medicine principles 
to determine the quality and level of the 
evidence. 
 To provide a context and rationale for the 
aims, objectives and outcomes of the 
proposed research project to be 
conducted. 
c) Literature search strategy 
UCT Libraries’ online portal served as the base for 
the literature search using the following databases: 
MEDLINE, WorldCat.org, Academic OneFile, SA 
ePublications Journal Collection, Science Direct, 
BioMed Central, Google Scholar and Pubmed. 
Keywords used to search for literature included 
‘human immunodeficiency virus’, ‘pregnant’, 
‘breastfeeding’, ‘mother to child transmission’, 
‘vertical transmission’, ‘CD4’, ‘adherence’, 
‘compliance’, ‘retention’, ‘attrition’, ‘antiretroviral 
treatment’, ‘Option B+’, ‘international’, ‘Sub-
Saharan Africa’, ‘South Africa’. 
d) Quality, Inclusion & Exclusion Criteria 
The principal researcher screened the identified 
literature for relevance and only included peer 
reviewed articles, articles published in English and 
papers published up to 1 April 2015. 
e) Literature Review 
Extensive research has been conducted on HIV 
PMTCT with overwhelming evidence 
demonstrating the effectiveness of ART in reducing 
vertical transmission of HIV during pregnancy and 
breastfeeding when compared to no ART or short 
course PMTCT.(1,2)  Subsequently, patient 
adherence became important, with retention in 
care receiving increased research interest.  
Retention rates vary significantly between studies, 
depending on factors such as patient population, 
institutional differences and treatment protocols.(3) 
The introduction of ‘Option B +’ in Malawi in 2010 
served as a global pilot program for universal life 
long ART initiated during pregnancy and 
breastfeeding.(4)  Despite the program’s positive 
outcomes, concerns have been raised regarding 
patient retention in care, especially among patients 
initiated on ART at CD4 counts above 350 cells/ųl 
or WHO Stages 1 or 2.(4, 5) 
Despite controversies the WHO revised ART 
guidelines in 2012 allowing for both ‘Option B’ and 
‘Option B +’ as regimen options depending on 
individual region factors.(6)  In 2013 the South 
African Department of Health adopted ‘Option B’ 
as the national standard of care while the Western 
Cape adopted ‘Option B +’.(7)  Similar to the Malawi 
program, patient retention has been questioned in 
the Western Cape especially taking into 
consideration the discrepancy with national 
guidelines. 
Defining the problem 
Despite the evident importance of retention in 
care, no definition for lost to follow up (LTFU) has 
been standardised with inconsistencies in available 
published research.(8)  Patient misclassification as 
either LTFU or “in active care” is a major obstacle 
in determining true attrition rate impacting 
comparison between facilities and implementation 
of interventions.(8) 
In an attempt to generate an empirical LTFU 
definition for adults on ART Chi, Yiannoutsos et al 
conducted a systematic review on available 
literature in 2011.(8)  The authors obtained data 
from the International Epidemiology Database to 
Evaluate Adult Immunodeficiency Syndrome 
(IeDEA) which contains information from 7 
international regions consisting of 41 countries’ 
facilities specifically including regions with the 
highest incidence of HIV.(8) 
The primary analysis of this study identified the 
most accurate definition of LTFU to be 180 days 
since the patient’s last visit with a narrow 95% 
confidence interval of 173 – 181 days.(8)  Further 
analysis showed that applying this definition had a 
sensitivity of 77,6%(95% CI: 77,3% - 78%), 
specificity of 97,1%(95% CI: 97% - 97,2%), positive 
predictive value of 89,9%(95% CI: 89,6% - 90,2%) 
and a negative predictive value of 93%(95% CI: 
92,8% - 93,1%).(8)  Misclassification of patients as 
LTFU or “in active care” only amounted to 7,7%, 
the lowest rate in all threshold comparisons.(8)  
Furthermore, the high positive and negative 
predictive values of the suggested definition 
supported by narrow 95% confidence intervals are 
compelling.(8)  Nonetheless, considering the 
significant heterogeneity among regions, the 
authors identify a standardised global LTFU 
definition as a potential study limitation.(8)  This 
implies that in certain contexts, locally applicable 
LTFU definitions tailored to unique challenges may 
be more appropriate than the article’s 
recommended definition.(8) 
 
Vertical transmission reduction 
Before introduction of PMTCT programs, HIV 
infection rate among breastfed infants in 
developing countries was estimated to be as high 
as 25% - 35% in the first 6 months.(9)  This shifted 
global research towards HIV PMTCT and ultimately 
led to the birth of the UNAIDS Global plan towards 
the elimination of new HIV infections among 
children and keeping their mothers alive.(10) 
One of the most significant studies that 
revolutionised HIV PMTCT is the Kesho Bora study 
conducted in Burkina Faso, Kenya and South Africa 
between 2005 and 2008.(1)  This blinded, 
randomised control trial compared HIV MTCT in 
breastfeeding mothers on triple ART to that in 
breastfeeding mothers on antepartum zidovudine 
and single dose nevirapine prophylaxis in labour.(1)  
The study primarily aimed to compare HIV vertical 
transmission between the groups by determining 
infant HIV status at 6 weeks and 12 months 
postpartum.(1) 
The results of this trial revolutionised PMTCT and 
views on feeding practices in HIV exposed infants 
worldwide.  HIV MTCT in the triple ART group was 
5.4% at 12 months (95% CI: 3.6 – 8.1%) and 9.5% 
(95% CI: 7.0 – 12.9%) in the control group.(1)  This 
translates into a statistically significant 43% 
relative risk reduction in HIV MTCT 12 months 
postpartum in patients on triple ART compared to 
those on the zidovudine/nevirapine PMTCT 
regimen (p=0.029).(1) 
In resource limited settings where breastfeeding is 
vital, the Kesho Bora study unequivocally 
demonstrated that triple ART during pregnancy 
and breastfeeding significantly reduces HIV 
MTCT.(1) 
In 2009, the Kisumu Breastfeeding Study 
conducted in Kenya published results confirming 
the findings of the Kesho Bora study.(2)  This single 
arm clinical intervention trial assessed HIV MTCT 
reduction using triple ART initiated at 34 weeks 
gestation until 6 months postpartum while 
exclusively breastfeeding when compared to single 
dose nevirapine.(2)  Results showed HIV MTCT rates 
of 4.2% (95% CI: 2.7% - 6.4%) at 6 weeks 
postpartum and 6.7% (95% CI: 4.8% - 9.4%) at 18 
months.(2)  Most importantly, Kisumu’s finding of 
5.0% (95% CI: 3.4% - 7.4%) cumulative transmission 
rate 6 months postpartum correlates with Kesho 
Bora’s vertical transmission rate at 6 months of 
4.9% (95% CI: 3.1% - 7.5%).(1,2)  Given these 
findings, it is evident that triple ART initiated in 
pregnancy and breastfeeding significantly reduces 
HIV MTCT compared to zidovudine/nevirapine.(1,2) 
Retention is Vital 
Adherence is vital in all patients on ART, but 
especially in HIV positive pregnant and 
breastfeeding women to preserve maternal health, 
diminish the development of drug resistance and 
prevent MTCT of HIV.(11)  Studies determining the 
required level of ART adherence to sustain 
virological suppression in patients on current ART 
regimens have shown that adherence rates as low 
as 70–80% sufficiently suppress the virus.(11)  
However, these studies emphasize that much more 
favourable  outcomes can be achieved with better 
adherence, thereby continuing to highlight the 
importance of optimal ART adherence.(11)   
In pregnant and breastfeeding women this is 
particularly important to ensure the lowest 
possible risk of MTCT and to achieve the WHO 
target of eliminating new vertical HIV infections by 
2015.(10) 
A 2010 retrospective cohort study conducted by 
Clouse et al. in Johannesburg, South Africa, looked 
at LTFU of newly diagnosed HIV positive pregnant 
women before and after delivery.(12)  The authors 
shared international concerns of increased 
postpartum LTFU once infants are no longer at risk 
of vertical transmission.(12) 
The study defines LTFU as one month or longer 
since last scheduled visit.(12)  Considering the 
average global consensus of 180 days since last 
visit, this definition seems stringent and could 
overestimate attrition.(12)  The authors calculated 
the cumulative retention of ART eligible patients 
(i.e. those with  CD4 cell counts <350 cells/ųl or 
WHO Stage 3 or 4) as 40.5% (95% CI: 32.3 - 49.0%) 
from testing, through delivery, until 6 months after 
ART initiation.(12)  Of note, even at the upper limit 
of a rather wide 95% confidence interval (49%), 
retention remains poor.(12)  The same calculation 
for the ART ineligible group showed an even lower 
22.6% cumulative retention from booking through 
6 months postpartum (95% CI: 15.9 – 30.6%).(12)  As 
with the ART eligible group, the wide 95% 
confidence interval does not necessarily alter the 
conclusion that retention in ART care during 
pregnancy is poor.(12) 
Additionally, a baseline CD4 cell count of >350 
cells/ųl was shown to be strongly associated with 
LTFU.(12)  Patients with CD4 cell counts >350 cells/ųl 
at antenatal booking had a 3.3 times higher risk of 
becoming LTFU compared to their lower CD4 cell 
count counterparts (aHR 3.30; 95% CI: 1.95 – 
5.58).(12)  Conversely, being over 30 years of age at 
ART initiation was associated with increased 
retention in longterm care (aHR 0.49; 95% CI: 0.30 
– 0.81).(12) 
The study resonates global concerns that retention 
of pregnant HIV positive patients in ART care is 
suboptimal, especially during the postnatal 
period.(12)  Indeed,  results in patients with CD4 cell 
counts>350 cells/ųl are alarming, with less than a 
quarter of these patients still in care 6 months 
after ART initiation.(12) 
It is evident that retention before implementation 
of ‘Option B+’ was suboptimal, with overall 
adherence rates below even the lowest acceptable 
rate to achieve viral suppression.(12)  Furthermore, 
postpartum adherence (particularly once infant 
HIV exposure ceases) declines progressively, with 
concerning implications regarding resistance and 
maternal health.(12) 
A progressive PMTCT pilot study implementing 
rapid ART initiation in pregnancy was launched in 
Cape Town in 2011.(13)  It applied ‘Option B+’ 
principles similar to those in the Malawian 
guidelines at the time providing triple ART to all 
HIV positive pregnant patients regardless of CD4 
cell count or WHO staging.(13)  Investigators aimed 
to demonstrate the program’s proposed benefits 
(which included markedly increased uptake in 
antenatal ART care and significantly reduced 
perinatal HIV transmission rates) in an attempt to 
motivate for national adoption of ‘Option B+’ 
guidelines.(13)  Their results revealed a remarkable 
ART initiation rate of 91% at antenatal booking 
visit.(13)  Consequently, antenatal ART exposure was 
optimised with complete viral load suppression at 
delivery in 75.8% of patients and a negligible 
vertical transmission rate of 0.9%.(13) 
The marked success of rapid ART initiation 
demonstrated by this study supported the 
international shift to ‘Option B/B+’ with undoubted 
benefits to both mother and infant as shown in 
literature to date.(4, 13, 15)  In appropriate settings, 
specifically developing countries, this simplified 
algorithm seems the long awaited solution to 
major obstacles and the publication of revised 
guidelines only a matter of time. 
The birth of Option B+ 
In 2010 the WHO revised PMTCT guidelines to 
include ‘Option B’ as well as the already well 
established ‘Option A’.(14)  Nonetheless, several 
factors, especially in Sub-Saharan countries, 
continued to complicate ART initiation and served 
as barriers to early initiation with consequent 
inadequate maternal viral load suppression before 
birth.(16) 
Malawi identified shortcomings in their PMTCT 
program early on and implemented ‘Option B+’ as 
a feasible alternative regimen.(15)  In a 2011 Lancet 
article, Schouten et al debate the proposed 
regimen and identify limited access to CD4 cell 
count testing, high fertility rates, late antenatal 
booking and extended breastfeeding as major 
barriers to timeous implementation of PMTCT ART 
in Malawi.(16) 
Responding to widespread criticism of Malawi’s 
immediate adoption of ‘Option B+’ without a 
preceding pilot project, the authors propose the 
regimen’s excellent safety profile, limited access to 
CD4 cell count testing and the urgency of 
expanding the country’s PMTCT coverage as 
adequate motivation for the decision.(16)  Schouten 
et al additionally refute global concerns of 
increased attrition rates among healthy women 
with high CD4 cell counts in long term ART care.(16)  
They cite continuous viral load suppression in short 
succession pregnancies, reduction of opportunistic 
infections and a decreased maternal mortality rate 
as compelling reasons in support of life long triple 
ART.(16) 
The Malawian Ministry of Health (MOH) 
implemented ‘Option B+’ in 2011 with promising 
expectations of decreased morbidity and mortality 
and improved HIV PMTCT.(4)  Initial outcomes were 
positive, with a seven fold increase in PMTCT 
coverage during the first year and a retention rate 
of 76,9% 12 months after ART initiation.(4)  Despite 
retention comparable to that prior to ‘Option B+’, 
concerns around long term sustainability continued 
to surface.(15)  Sceptics suspected high attrition 
rates among patients with high CD4 cell counts or 
WHO stage 1 or 2 particularly once infants were no 
longer at risk of vertical HIV transmission.(15) 
These concerns  prompted a study by the MOH 
published in AIDS in 2014 aiming to accurately 
determine retention rates among ‘Option B+’ 
patients in Malawi.(4) 
The study conducted by Tenthani et al, consisted of 
two parts.  One explored general patient retention 
at Malawian ART facilities, and the second aimed 
to determine LTFU among pregnant and 
breastfeeding women on ‘Option B+’ compared to 
non-pregnant women starting ART for their own 
health.(4) 
At facility level the investigators’ primary outcome 
determined the proportion of pregnant HIV 
positive patients LTFU 6 months after ART 
initiation.(4)  Data for this part of the study was 
obtained through MOH quarterly HIV program 
reports containing information from governmental 
audits.(4)  Considering the lack of external audits 
and independent data, information bias cannot be 
definitively excluded in this study arm.(4) 
Facility selection included all ART/PMTCT clinics in 
Malawi.(4)  Although this ensures a comprehensive 
assessment of the national retention rate it has 
potential pitfalls.  Significant differences in facility 
sizes increase the possibility of variable intensity 
patient care.(4)  Similarly, faith-based and private 
clinics could provide different standards of care 
compared to public clinics further complicating 
comparison.(4)  To compensate for this 
heterogeneity amongst facilities, investigators 
appropriately use random-effects meta-
regression.(4)  After determining the proportion of 
patients LTFU at each facility researchers calculate 
site-specific log odds and performed a meta-
analysis to determine predictors of LTFU among 
‘Option B+’ women in Malawi.(4) 
The patient level section of the study complements 
facility level outcomes, but also measures 
individual patient retention through a 
retrospective cohort design comparing ‘Option B+’ 
patients to a non-pregnant female control group.(4)  
The researchers identify no follow up visit after 
ART initiation and the proportion of patients LTFU 
as primary outcomes.(4)  A clear patient selection 
flow diagram demonstrates exclusion criteria such 
as male gender or age less than 50 years which 
decreases potential confounding factors that could 
impact study outcomes.  However, authors only 
include facilities using electronic medical 
recordkeeping systems, consequently excluding 
Northern Malawian facilities using paper-based 
records.(4)  This potentially renders the study 
sample non-representative of the entire Malawian 
HIV positive female population.(4) 
The study’s data collection occurred in three 
cohort groups, with pregnant and breastfeeding 
women initiated on ‘Option B+’ as the two 
intervention groups and non-pregnant women 
initiating ART for own health as the control 
group.(4)  Tenthani et al applied identical selection 
criteria, follow up and outcome criteria for all 
groups, excluding potential bias.(4)  Results showed 
an overall attrition rate of 17.1% 6 months after 
ART initiation.(4) 
Patient level data analysis found pregnant patients 
five times more likely (aOR 5.0, 95% CI: 4.2 – 6.1) 
and breastfeeding women twice as likely to be 
LTFU (aOR 2.2, 95% CI: 1.8 – 2.8) compared to 
women starting ART for own health.(4) 
Researchers attempted to identify predictors of 
LTFU as an additional outcome.(4)  Patients at urban 
facilities demonstrated a 1.4 times greater risk of 
attrition than those at rural facilities, but a 95% 
confidence interval of 1.0 – 2.0 renders this result 
statistically less significant.(4)  Similar limitations 
invalidate attrition risk comparison between 
different types of facilities.(4)  Six months after ART 
initiation 29.4% (95% CI: 27.6 – 31.3%) of ‘Option 
B+’ pregnant women and 16.1% (95% CI: 14.3 – 
18.0%) among ‘Option B+’ breastfeeding patients 
were classified as LTFU.(4)  Compared to a 6 month 
attrition rate of 9.6% (95% CI: 8.7 – 10.6%) among 
women initiating ART for own health,  the higher 
rate of LTFU among ‘Option B+’ patients is 
evident.(4) 
The study has certain limitations with the most 
significant being incomplete data from electronic 
records attributed to the retrospective study 
design and short follow up time.(4)  Most studies 
report on retention for up to at least 12 months 
after ART initiation to better reflect true attrition 
rate.  The limited 6 month follow up by Tenthani et 
al could overestimate retention and consequently 
render study outcomes difficult to compare and 
extrapolate globally.(4) 
Malawi’s pilot project reignited global controversy 
around ‘Option B+’.  In a Lancet 2013 publication 
Coutsoudis et al. question ‘Option B+’ feasibility 
and label Malawi’s program “extreme” and an 
unscientific “test and treat” approach.(18)  In 
response, the WHO dismisses Coutsoudis et al’s 
criticism and supports the global positive but 
cautionary view on ‘Option B+’.(19)  They suggest 
implementing ‘Option B+’ in resource limited 
settings, should the advantages of the program 
outweigh potential pitfalls.(19) 
Zimbabwe implemented ‘Option B+’ in September 
2013.  Motivated by global concerns, retention in 
ART care were scrutinised in a retrospective cohort 
study by Dzangare et al in 2014.  They showed six 
month LTFU amongst ‘Option B+’ women of 15.9%, 
significantly less than Malawi’s 29.4% at the same 
time post ART initiation.(22) 
The study additionally identified age and gravida 
status as significant risk factors for attrition.  
Adolescent females were found to be more at risk 
of attrition.  This is evident in the finding that 
women aged between 20 – 25 years were 0.2 times 
as likely to be LTFU (aRR 0.2, 95% CI: 0.1 – 0.5, 
p=0.000) than those aged 15 – 19 years.  
Additionally women that were gravida 3 were 7.4 
times more likely to be LTFU compared to 
primigravidas (aRR 7.4, 95% CI: 1.7 – 32.5, p = 
0.008).  Despite demonstrated statistical 
significance (p<0.05), the wide 95% confidence 
interval of the latter result renders it less 
generalisable.(22) 
Although this study resonates with prior research 
findings, its small study sample and inclusion of 
only two rural districts in Zimbabwe further limits 
its extrapolation value.  However, as the authors 
aptly identify, the study serves to confirm the 
importance of ‘Option B+’ in PMTCT and highlights 
the need for continued research and interventions 
to reduce attrition.(22) 
After implementing ‘Option B+’ in 2013 Ethiopia 
similarly lacked data on patient retention.  A 
retrospective cohort study published in the Journal 
of the International AIDS society in March 2016 
explored LTFU rate among pregnant women 
initiated on ‘Option B+’ between March 2013 and 
April 2015.(23) 
The investigators had clearly defined selection 
criteria and definitions such as LTFU being 90 days 
after the last clinic visit.  This definition is in 
keeping with the majority of international research 
simplifying direct comparison between studies.  
Participant selection occurred through an all-
inclusive method and all participants excluded 
from the study was accounted for with valid 
reasons avoiding selection bias.(23) 
The study outcomes showed a 6 month attrition 
rate of 11.9% (95% CI: 8.9 - 16.0%) and LTFU at 12 
months of 15.7% (95% CI: 12.0 - 20.4%).  Although 
this is lower than the attrition rate found in other 
studies, it could be attributed to different PMTCT 
models between countries, varying LTFU 
definitions and other study setting 
incompatibilities.(23)  Considering the impact these 
factors could potentially have on the study 
outcomes, the results should be interpreted 
cautiously and further research conducted. 
Another Ethiopian-based study is in keeping with 
previous studies’ findings that ART initiation rate 
and age are significant predictors of LTFU.  Women 
that had same day ART initiation were twice as 
likely to be LTFU (aHR 1.9, 95% CI: 1.1 to 3.2, 
p=0.032) compared to those initiated at a later 
stage.  Possible reasons cited include the inability 
to disclose and lack of readiness to commit to 
lifelong treatment.  Additionally, age between 18 
and 24 years was associated with a 2.3 times 
increased risk of attrition (aHR 2.3, 95% CI 1.2 to 
4.5, p=0.017).  With narrow confidence intervals 
and statistically significant p-values these 
outcomes can be considered valid and 
generalizable to other settings.(23) 
The incorporation of ‘Option B+’ into the revised 
WHO PMTCT Guidelines affirmed confidence in its 
use in eligible, resource limited settings.(6)  
Subsequently, South Africa published revised 
National ART Guidelines in 2013 adopting ‘Option 
B’ as the main regimen with the Western Cape 
Department of Health opting to implement ‘Option 
B+’.(7,20) 
f) Gaps & Future Research 
Two years after the implementation of ‘Option B+’ 
in the Western Cape, important questions remain 
unanswered.  While success is evident in the 
increased uptake of pregnant patients in ART care, 
decentralisation of services and expanded nurse-
initiated ART coverage, growing concerns remain 
regarding patient retention in long term ART care, 
especially once infants are no longer at risk of 
vertical transmission.(21) 
Despite several recent publications investigating 
‘Option B+’ retention and long term outcomes it is 
imperative that continued research be conducted. 
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Background: The implementation of 'Option B+' has increased uptake and access to antiretroviral (ART) care. 
However, growing concerns exist regarding retention, especially once vertical transmission risk ceases. 
Considering the importance of adherence to achieve virological suppression and avoid resistance research on 
retention is crucial. This study compares the retention of women initiated on 'Option B+' to that of women 
initiating ART for their own health. Additionally possible predictors of loss to follow-up (LTFU) were 
explored. 
Methods: Women initiating ART between 1 April and 31 August 2013 were allocated to either the pregnant 
(n=228) or non-pregnant (n=177) cohort. Retrospective review of electronic recordkeeping systems and patient 
folders measured retention up to 15 months after ART initiation. Demographic data was captured to explore 
predictors of LTFU. To avoid outcome bias with participants transferred out, analysis included a ‘worst case’ 
scenario assuming LTFU of all these participants and a ‘best case’ scenario assuming continued retention in 
care. 
Results: At 6 months ‘best case’ analysis showed 28.1% of pregnant women LTFU compared to 16.9% of non-
pregnant women with a 1.3 times greater attrition risk among pregnant cohorts (RR 1.29; 95% CI 1.09 – 1.54; 
p=0.009).  ‘Worst case’ analysis at 6 months showed pregnant women at 1.4 times larger LTFU risk (RR 1.42; 
95% CI 1.20 – 1.67; p<0.0001).  Despite ‘best case’ analysis LTFU at 15 months increased to 41.2% in the 
pregnant group compared to 30.5% in non-pregnant patients and pregnant women remained at a 1.2 times 
greater attrition risk (RR 1.22; 95% CI 1.03- 1.44; p=0.03).  Significant predictors of LTFU were age over 41 
years (HR 17.2; 96% CI 1.8 - 163.0; p=0.013) and WHO clinical stage 3 (HR 4.2; 95% CI 1.6 - 10.8; p=0.004). 
Marital status, employment, baseline CD4 cell count and clinic distance were not significant predictors. 
Conclusion: Similar to previous research, we found HIV positive pregnant women at significantly higher risk 
to be LTFU compared to non-pregnant women. Given the global focus on the elimination of vertical HIV 
transmission and retention in ART care, we hope our findings will enrich the ongoing conversation on how best 
to implement and revise PMTCT guidelines. 
Keywords: Attrition, Retention, Antiretroviral, Option B+, Predictors, Pregnant. 
Definitions 
 Option A: Zidovudine (AZT) to HIV positive pregnant
women not qualifying for lifelong triple ART from 14
weeks gestation with single dose nevirapine and 
tenofovir/emtracitibine 3 hourly in labour. 
(12)
 Option B: Universal ART to all HIV positive pregnant
women.  Patients with CD4 counts less than 350 or
WHO stage 3 or 4 continue lifelong while others 
discontinue ART one week after cessation of
breastfeeding. 
(9,10)
 Option B +: Lifelong ART to all pregnant and 
breastfeeding HIV positive women regardless of
CD4 count or WHO clinical staging. 
(9,10)
 Lost to follow up: Not attending ART care for 90
days or longer after the last visit.  The definition is 
based on current standard of practice at the study
sites and a comprehensive literature review. 
(6,13)
 Never returning for follow up: Never returning to
ART care after the first visit.
 Transfer Out: Transfer to another ART facility
documented in the clinical notes or on the ERKS.
Extensive research has been conducted on Human 
Immunodeficiency Virus (HIV) prevention of 
mother-to-child transmission (PMTCT) with 
overwhelming evidence demonstrating the 
effectiveness of antiretroviral treatment (ART) in 
reducing vertical transmission of HIV during 
pregnancy and breastfeeding. (1, 2) 
Adherence rates as low as 70–80 % can sufficiently 
suppress the virus, but much more favourable 
virological outcomes are possible with increased 
adherence.(3)  In pregnant and breastfeeding women, 
suppression is particularly important to ensure the 
lowest possible risk of mother-to-child transmission 
(MTCT) and to eliminate new vertical HIV 
infections.(4, 5)  Retention rates between studies vary 
significantly, depending on factors such as patient 
population, institutional differences and treatment 
protocols.(6) 
Several challenges threaten the success of PMTCT 
in developing countries including high HIV 
prevalence rates complicated by factors such as 
short birth intervals and late antenatal bookings.(7)  
Furthermore, insufficient laboratory resources cause 
delayed CD4 cell count testing, unnecessary ART 
deferral and consequently higher MTCT and 
maternal morbidity and mortality.(7) 
In response, Malawi launched the ‘Option B+’ pilot 
program in 2011, implementing rapid testing and 
same day lifelong ART initiation for all HIV 
positive pregnant and breastfeeding women.(7)  
Concerns around long term feasibility of the 
regimen surfaced,(8) but largely positive outcomes 
ultimately led to updated World Health 
Organisation (WHO) ART guidelines in 2012.(9) 
Shortly after the release of updated guidelines 
several countries including Zimbabwe and Ethiopia 
followed suit and implemented ‘Option B+’.(19,20)  
Equally alarming attrition rates echoed existing 
global concerns, but the studies demonstrated much 
improved PMTCT access and availability 
complicating criticism of the program.(19,20) 
Experiencing similar challenges, South Africa 
revised its ART guidelines in April 2013 with the 
Western Cape implementing ‘Option B+’.(10) 
Three years after the implementation of ‘Option 
B+’ in the Western Cape, important questions 
remain unanswered.  While success is evident in 
increased accessibility, decentralisation of services 
and expanded nurse-initiated ART coverage, 
growing concerns remain regarding retention in 
long term care, especially once vertical 
transmission risk ends.(11) 
Evidently, further research in this area is crucial for 
the ongoing development of retention strategies and 
future decisions around regimen choices for 
individual provinces. 
Study Outcomes 
The primary outcome aims to determine the 
retention of HIV positive pregnant and 
breastfeeding women initiated on ‘Option B+’ in 
the Klipfontein/Mitchells Plain substructure in Cape 
Town and compare this to the retention of HIV 
positive women initiated on ART for their own 
health (CD4 count<350 cells/ųl or WHO clinical 
stage 3 or 4). 
The study’s secondary outcome aims to explore 
possible predictors of LTFU among ‘Option B+’ 
patients. 
Study Site(s)  
Western Cape ART services have been 
decentralised mostly to primary care level, with 
successful integration of antenatal and PMTCT 
services across the province.  Attending one site for 
ART, antenatal- and postnatal care has advantages 
such as increased patient centredness and better 
resource allocation. 
Hanover Park Community Health Centre (CHC) 
and Mitchells Plain CHC were selected as study 
sites for reasons such as having onsite Midwife 
Obstetric Units (MOU), integrated ART services, 
and implementation of ‘Option B+’ from 1 April 
2013 in accordance with the provincial ART 
guidelines. 
At both facilities pregnant women are initiated on 
ART at the onsite MOU and follow up continued at 
the ART onsite clinic.  ART initiation and follow 
up of non-pregnant patients take place at the very 
same facilities’ onsite ART clinics. 
Participants 
Participants included were female, ART naïve (i.e. 
no exposure to previous PMTCT or triple ART), 
older than 16 years of age, and initiated ART 
between 1 April and 31 August 2013. 
Participants were assigned to one of two cohort 
groups based on their pregnancy status at ART 
initiation.  The cohort group consisted of pregnant 
women who started antenatal care at the study sites 
during the specified time period and met the other 
inclusion criteria.  Under ‘Option B+’ guidelines, 
participants in this group could have any CD4 count 
and WHO clinical staging at initiation.(9, 10) 
The control group consisted of non-pregnant, HIV 
positive women who initiated ART at the included 
ART sites during the study period.  Owing to the 
provincial adult ART eligibility guidelines at the 
time these participants had CD4 counts <350 
cells/ųl and/or were WHO clinical stage 3 or 4.(10) 
Participants were not excluded based on other 
demographic characteristics. 
Participant Sampling 
The initial proposal to sample participants using the 
MOU Advise, Counsel, Test, Support (ACTS) 
registers at the two study sites was amended due to 
certain limitations.  These included the registers’ 
lack of comprehensive patient information and 
concerns regarding counsellor vigilance in 
recording every tested patient, thereby increasing 
the likelihood of missing patients during sampling. 
As a result the respective electronic record keeping 
systems (ERKS) at the study sites were used to 
identify participants meeting the selection criteria.  
Hanover Park CHC has Tier.net as an ERKS while 
Mitchells Plain CHC uses Ekapa.  Dedicated ERKS 
data capturers at ART sites ensure more accurate 
electronic records thereby significantly decreasing 
the possibility of incomplete participant sampling 
when used as a data source. 
Patient selection with Tier.net was done applying 
the filters “female”, “pregnant”, “non-pregnant” 
and “1 April 2013 – 31 August 2013”, consequently 
generating two cohort groups from the onset. 
Due to innate differences in Ekapa it was not 
possible to similarly apply these filters during 
sampling at Mitchells Plain CHC.  Instead, 
collaboration with the University of Cape Town’s 
information technologists generated a combined list 
of participants meeting the inclusion criteria.  
Unfortunately pregnancy status could not be 
differentiated and cohort allocation could only be 
done after individual folder review.  
Following participant selection (Figure 1) 
the pregnant cohort group comprised of 
228 participants and the non-pregnant 
control group included 177 women. 
Data Collection 
The principle investigator used pre-
programmed Excel spread sheets as data 
collection tools.  Participant demographic 
data was collected through individual 
folder reviews and cross-checked or 
supplemented with ERKS. 
Retention in care was determined through 
clinical notes review to ascertain 
participant attendance at the first visit and 
1, 3, 6, 9, 12 and 15 months after ART 
initiation.  To account for reasons other 
than true attrition ‘transfer out’ and ‘death’ 
were additional outcomes. 
Ethical Considerations 
Ethics approval for the study was granted 
by both the Human Research Ethics 
Committee of the University of Cape Town (HREC 
607/2014) and the Western Cape Provincial 
Research Ethics Committee. 
Data Analysis 
Data was captured using Excel version 14.0.0 
(Microsoft, USA, 2011) and analysis performed 
with SPSS version 22.0.0.0 (IBM, USA, 2015). 
Patient demographic characteristics were described 
as proportions (%).  The skewness and kurtosis 
scores confirmed normal distribution of data.  To 
calculate and quantify LTFU, risk ratios were 
calculated for each cohort.  Odds ratios are 
additionally included in the results. 
To avoid outcome bias with participants transferred 
to other facilities, analysis included a ‘worst case 
scenario’ assuming LTFU of all these participants 
and a ‘best case scenario’ assuming continued 
participant retention in care. 
The Pearson’s χ2 test (with its accompanying 
contingency coefficient) or Fischer’s exact test were 
used to calculate the statistical significance of the 
different proportions and risk ratios.  Independent 
Sample t-tests were used to test additional 
hypotheses.  The Cox proportional hazards 
regression model was used to determine predictors 
of LTFU, expressed as hazard ratios with 95% 
confidence intervals.  The log-rank test was used to 
test the significance of observed differences.  
Statistical significance was accepted as p<0.05. 
Results 
A total number of 274 patients initiated ART at 
Hanover Park CHC between 1 April and 31 August 
2013 (Figure 1).  After excluding males and 
participants younger than 16 years of age, 218 
participants were identified and allocated to the 
pregnant (134) and non-pregnant (84) cohorts 
respectively.  Folder and ERKS review excluded 
non- naïve ART participants and subsequently 
generated the final Hanover Park cohorts of 101 
pregnant and 58 non-pregnant participants. 
The Ekapa database identified 298 new ART 
patients at Mitchells Plain CHC during the study 
period.  As clarified earlier the exclusion of 48 ART 
non-naïve patients and 4 children preceded cohort 
allocation, finally producing the site’s study groups 
of 127 pregnant and 119 non-pregnant participants. 
Baseline patient demographic data is outlined in 
Table 1.  When comparing age, distribution across 
the four age categories was not similar, but 
differences between similar ranges were statistically 
significant. (p<0.0001) 
81.1% of pregnant cohorts live within the City of 
Cape Town’s ideal 5 kilometer travelling distance 
from the clinic compared to 70.1% of non-pregnant 
females residing in the same radius. (p=0.01) 
CD4 cell count distribution between the pregnant 
and non-pregnant group differed, with the majority 
of non-pregnant females (97.8%) having baseline 
CD4 cell counts < 350 cells/µl (p<0.0001).  The 4 
non-pregnant women with baseline CD4 cell counts 
> 350 cells/µl qualified for ART based on their 
WHO clinical stage.  In the pregnant cohort, CD4 
cell counts were fairly equally distributed with 
around 28% participants in each of the categories 
above 200 cells/µl. (p<0.0001) 
The majority of participants in both cohorts had a 
baseline WHO stage of 1 at 91.2% of pregnant and 
43.5% of non-pregnant women respectively. 
(p<0.0001) 
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Odds Ratio (OR) 
(95% CI) 
First Visit 12 (5.3) 7 (4) 1.13 (0.79 – 1.61) 0.64 - 0.01 1.35 (0.52 – 3.50) 
Month 1 19 (8.3) 18 (10.2) 0.90 (0.65 – 1.25) 0.60 - 0.04 0.80 (0.41 – 1.58) 
Month 2 27 (11.8) 19 (10.7) 1.05 (0.81 – 1.36) 0.75 - 0.01 1.02 (0.55 – 1.89) 
Month 3 43 (18.9) 26 (14.7) 1.13 (0.92 – 1.39) 0.29 - 0.04 1.35 (0.79 – 2.30) 
Month 6 97 (42.5) 42 (23.7) 1.42 (1.20 – 1.67) <0.0001 - 0.19 2.3 (1.54 – 3.68) 
Month 12 133 (58.3) 70 (39.5) 1.39 (1.17 – 1.66) 0.0002 - 0.19 2.14 (1.43 – 3.19) 
Month 15 146 (64) 75 (42.4) 1.48 (1.23 – 1.79) <0.0001 - 0.22 2.42 (1.62 – 3.62) 














Odds Ratio (OR) 
(95% CI) 
First Visit 12 (5.3) 6 (3.4) 1.19 (0.85 – 1.67) 0.47 - 0.02 1.58 (0.58 – 4.31) 
Month 1 19 (8.3) 15 (8.5) 0.99 (0.73 – 1.36) 1.00 - 0.002 0.98 (0.48 – 1.99) 
Month 2 27 (11.8) 16 (9.0) 1.13 (0.88 – 1.45) 0.42 - 0.02 1.35 (0.70 – 2.59) 
Month 3 38 (16.7) 20 (11.3) 1.20 (0.97 – 1.48) 0.15 - 0.05 1.57 (0.88 – 2.80 
Month 6 64 (28.1) 30 (16.9) 1.29 (1.09 – 1.54) 0.009 - 0.11 1.91 (1.17 – 3.11) 
Month 12 84 (36.8) 50 (28.2) 1.18 (0.99 – 1.40) 0.07 - 0.09 1.48 (0.97 – 2.26) 
Month 15 94 (41.2) 54 (30.5) 1.22 (1.03 – 1.44) 0.03 - 0.11 1.60 (1.06 – 2.41) 
Interestingly, the majority of pregnant participants 
were diagnosed HIV positive within 6 months of 
ART initiation at 69.7% compared to 46.3% in the 
control group. (p<0.0001) 
In keeping with ‘Option B+’ the majority of 
pregnant cohorts received same day counselling 
(59.6%) or their counselling rate was unknown 
leaving only 14% of pregnant women not 
counselled according to the guidelines. 
The ‘worst case scenario’ showed 42.5% of HIV 
positive pregnant women to be LTFU 6 months 
after ART initiation compared to only 23.7% of 
their non-pregnant counterparts. (Table 2)  
Assuming retention of all transferred out pregnant 
women decreased this proportion to 28.1% 
pregnant and 16.9% non-pregnant women LTFU 
at 6 months. (p=0.009) (Table 3) 
At fifteen months, LTFU was 64% in the ‘worst 
case’ pregnant group compared to an equally 
suboptimal, but much lower, proportion of 42.4% 
in patients on ART for their own health. 
(p=0.0002)  Regardless of assuming the optimistic 
‘best case scenario’ retention of pregnant cohorts 
at 15 months remained comparatively poor with a 
41.2% attrition rate. (p=0.03) 
We further calculated the risk of HIV positive 
pregnant women to be LTFU relative to that of 
non-pregnant HIV positive patients.  Both odds 
ratios and relative risk were calculated and are 
included in the results.  However relative risks 
were primarily used in interpretation of study 
findings since outcome frequencies were greater 
than 10% and odds ratios could potentially 
overestimate the difference between cohorts.(21) 
At 6 months after ART initiation, ‘worst case’ 
pregnant cohorts were 1.4 times more likely to be 
LTFU (RR 1.42; 95% CI 1.20 – 1.67; p<0.0001) 
and despite assuming the ‘best case scenario’ 
attrition risk was still 1.29 times greater in this 
group. (RR 1.29; 95% CI 1.09 – 1.54; p=0.009)  
Moreover, the comparison at 15 months remained 
similar with a 1.2 times larger attrition risk in the 
pregnant, ‘best case’ cohort (RR 1.22; 95% CI 
1.03 – 1.44; p=0.03) and an unchanged 1.4 times 
greater LTFU risk assuming the ‘worst case’ 
scenario. (RR 1.48; 95% CI 1.23 – 1.79; 
p<0.0001) 
The risk difference between cohorts at 15 months 
showed non-pregnant women to be at 0.2 times 
(‘worst case’) and 0.1 times (‘best case’) less risk 
of being LTFU compared to their non-pregnant 
counterparts. 
Most of the factors investigated in this study were 
not statistically significant predictors of LTFU. 
(Table 4)  Assuming the ‘worst case’ 
demonstrated that age over 41 years predicted a 
17.2 times greater risk of LTFU, but the 
accompanying wide 95% confidence interval 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Being WHO stage 3 at ART initiation had a 4.2 
times larger attrition risk. (HR 4.2; 95% CI 1.6 – 
10.8; p=0.004)  The risk of being LTFU if pre-
ART initiation counselling was rapid (three 
sessions done over two days) or all done on the 
same day was much lower than the risk if only 
one session was done per week. (HR 0.02; 95% 
CI 0.001 – 0.2; p=0.001)  However, having only 
one participant in the normal counselling rate 
group could be the reason for this finding. 
Applying the ‘best case scenario’ to the same 
model yielded similar outcomes with age ≥ 41 
years (HR 39.9; 95% CI 3.2 – 469.5; p=0.04), 
WHO clinical stage 3 (HR 6.3; 95% 2.2 – 17.8; 
p<0.001) and counselling rate (HR 0.01; 95% CI 
0.001 – 0.2; p=0.02) being possible predictors of 
LTFU in the pregnant group. 
Discussion 
Pregnancy is associated with several physical, 
emotional and social challenges.  The added 
burden of an HIV positive diagnosis in pregnancy 
and pressure to start ART potentially threatens 
patient buy-in and commitment to lifelong 
treatment.(3) 
We found HIV positive pregnant women at least 
twice as likely to be LTFU as women starting 
ART for their own health with 36.8% (‘best case’) 
and 58.3% (‘worst case’) LTFU 12 months after 
ART initiation.  Results correlate with a 
Johannesburg-based study which similarly found 
57.5% attrition among pregnant women within 13 
months of testing HIV positive.(14) 
One of the most pertinent ‘Option B+’ studies to 
date (conducted in Malawi in 2014) demonstrated 
a 6 month attrition rate of 16.1%.(7)  At 6 months 
our study showed a much higher 42.5% (‘worst 
case’) and 28.1% (‘best case) LTFU rate during 
pregnancy with an approximately 1.4 times 
greater attrition risk compared to non-pregnant 
women. 
Despite the statistical significance (p<0.05) of the 
findings, it is notable that the confidence intervals 
(precision) of some of the risk ratios are wide and 
range from close to unity (one), which raises 
uncertainty about the findings.  Nonetheless, the 
results would likely be more convincing, with 
narrower confidence intervals in a larger scale 
study. 
Interestingly research conducted in Zimbabwe and 
Ethiopia after the implementation of ‘Option B+’ 
demonstrated much lower six month attrition rates 
of 15.9% and 11.9% among pregnant women 
respectively.(19,20)  This lower rate compared to 
our and Malawi’s study findings could be 
attributed to potentially different implementation 
of ‘Option B+’ models between countries, varying 
LTFU definitions and other study setting 
incompatibilities. 
Evaluation of the study outcomes seems to 
support our hypothesis that HIV positive pregnant 
women only remain in care until delivery or the 
cessation of breastfeeding.  Several reasons have 
been suggested with the most probable being 
mothers’ motivation to protect their unborn 
children, with external social and emotional 
pressures influencing their behaviour after 
delivery.(3)  This is demonstrated by the increasing 
LTFU over time, up to a considerable 41.2% or 
1.2 times greater attrition risk at 15 months even 
when assuming the optimistic ‘best case’ scenario. 
Another possible explanation could be most 
pregnant women’s good physical health at ART 
initiation.  The daily pill burden, possible side 
effects, as well as the implications of regular 
clinic visits, while completely asymptomatic, 
could explain the lack of incentive to remain in 
care.  Previous studies support this hypothesis, 
demonstrating higher attrition among patients at 
WHO stage 1 or 2.(13,15)  Although our study 
showed a 4.2 times higher attrition risk at WHO 
stage 3, the small subgroup sample means this 
finding should be viewed with caution. 
With the ‘test and treat’ premise of ‘Option B+’, 
attrition could also be a result of inadequate 
patient preparation to start and adhere to lifelong 
medication.  We showed counselling rate to be a 
significant predictor of LTFU, but considering 
that the majority of pregnant women received 
same day counselling, with only one participant 
counselled at the normal rate, deriving 
conclusions from this cohort would be 
problematic. 
Research has shown that disclosure and the 
recruitment of a treatment supporter prior to 
initiation has a positive impact on ART 
adherence.(16, 17)  With the ‘test and treat’ approach 
of ‘Option B+’ this is clearly not possible and 
could potentially impact the risk of attrition.  
However, disclosure has been found to be 
suboptimal even prior to the implementation of 
‘Option B+’ with fears around social isolation and 
stigmatisation cited as possible reasons.(18)  
Moreover, pregnant and breastfeeding women 
initiated on ‘Option A’ and ‘Option B’ have had 
equally concerning attrition rates, potentially 
highlighting issues with PMTCT in general, 
instead of ‘Option B+’ specifically.(3, 14) 
Evaluating predictors of LTFU revealed age over 
41 years, WHO stage 3 and counselling rate as 
significant predictors of LTFU.  Other factors 
such as employment, marital status and baseline 
CD4 cell count were not statistically significant 
predictors.  As mentioned earlier, the skewed 
distribution of pregnant participants in the three 
significant categories (with less than ten 
participants each) potentially undermine the 
results.  Nevertheless, their statistical significance 
could be confirmed and shown to be more 
generalizable, should the study be repeated on a 
larger scale. 
The study’s retrospective design has certain 
limitations that could impact findings.  Inadequate 
recordkeeping could result in incorrect or missing 
data which could change study outcomes by 
altering baseline data input. 
To avoid observer bias and “favourable” data 
capturing the principal researcher had 
predetermined categorical variables with clearly 
assigned values.  However, the risk of recording 
bias in retrospective studies is more difficult to 
exclude completely.  Although care was taken to 
correctly record data from the clinical notes 
illegible clinician handwriting was unavoidable at 
times. 
Considering the study’s limitations in light of its 
significant findings, it is advisable that further 
research be conducted in this area.  Studies with 
larger numbers of participants and more sites 
could improve both the statistical, and more 
importantly clinical, significance of the findings. 
Conclusion 
The findings of our study confirm both national 
and sub-Saharan research to date, where HIV 
among adolescent and young females is most 
prevalent.(4)  It confirms the suspected much 
higher attrition risk pregnant women have as early 
as 6 months after ART initiation and their 
increasing LTFU rates over time. 
Given the importance of adherence to achieve 
virological suppression and avoid resistance, 
interventions to improve retention are imperative.  
However, the inability of this and previous 
research to identify significant modifiable risk 
factors for LTFU among pregnant women makes 
intervention programs difficult to develop.  
However, we alternatively suggest continuous 
counselling and education of women throughout 
pregnancy.  In addition, actively tracing patients 
who become LTFU could improve retention, but 
might be challenging in resource-limited settings. 
The elimination of vertical transmission and 
retention in ART care remains a priority in the 
global HIV community.  While our study 
hopefully enriches ongoing conversations on the 
implementation and revision of the PMTCT 
guidelines, further research to continuously 
improve and positively impact this important 
issue is recommended. 
Conflicts of interest 
The authors have no conflicts of interest to 
declare. 
References 
1) The Kesho Bora Study Group. “Triple 
antiretroviral compared with zidovudine and 
single dose nevirapine prophylaxis during 
pregnancy and breastfeeding for prevention of 
mother to child transmission of HIV-1 (Kesho 
Bora study):a randomised controlled trial. Lancet 
Infect Dis. 2011 Jan 14; 11:171-80. 
2) Thomas T, Masaba R, Ndivo R, Zeh C, Misore A 
et al. Prevention of Mother-to-Child 
Transmission of HIV-1 among Breastfeeding 
Mothers Using HAART: the Kisumu 
Breastfeeding Study, Kenya: A Clinical Trial. 
PLoS Med. 2011 Mar 29; 8(3):1-12. 
3) Nachega JB, Olalekan AU, Anderson J, Peltzer 
K, Wampold S, Cotton MF et al. Adherence to 
antiretroviral therapy during and after pregnancy 
in low-income, middle-income and high-income 
countries: a systematic review and meta-analysis. 
AIDS. 2012 Aug 14; 26(16):2039-49. 
4) Joint United Nations Programme on HIV/AIDS 
(UNAIDS). Global plan towards the elimination 
of new HIV infections among children by 2015 
and keeping their mothers alive 2011 - 2015 




15 October 2015). 
5) Black S, Zulliger R, Myer L, Marcus R, Jeneker 
S, Taliep R. Safety, feasibility and efficacy of a 
rapid ART initiation in pregnancy pilot 
programme in Cape Town, South Africa. S Afr 
Med J. 2013 Aug; 103(8):557-62. 
6) Fox MP, Rosen S. Patient retention in 
antiretroviral therapy programs up to three 
years on treatment in sub-Saharan Africa, 
2007–2009 : systematic review. Trop Med Int 
Health 2010 Jun; 15(1):1-15. 
7) Tenthani L, Haas AD, Tweya H, Jahn A, van 
Oosterhout JJ, Chimbwandira F et al. Retention 
in care under universal antiretroviral therapy 
for HIV-infected pregnant and breastfeeding 
women (‘Option B+’) in Malawi. AIDS. 2014; 
28(4):589-98. 
8) Coutsoudis A, Goga A, Desmond C, Barron P, 
Black V, Coovadia H. Is Option B+ the best 
choice? Lancet. 2013 Jan 26; 381:1272-73. 
9) World Health Organisation. Use of 
antiretroviral drugs for treating pregnant 
women and preventing HIV infection in infants 
– programmatic update 2012 [Internet]. 
Geneva: WHO; 2012 p. 1-5. Available from: 
http://www.who.int/hiv/pub/mtct/programmatic
_update2012/en/ (accessed 11 November 
2015). 
10) National Department of Health South Africa. 
The revised antiretroviral treatment guidelines 





(accessed 20 November 2015). 
11) Clouse K, Schwartz S, Van Rie A, Bassett J, 
Yende N, Pettifor A. “What they wanted was 
to give birth; nothing else”: Barriers to 
retention in “Option B +” HIV Care among 
Postpartum Women in South Africa. J Acquir 





12) World Health Organisation. Antiretroviral
drugs for treating pregnant women and
preventing HIV infection in infants:
recommendations for a public health approach
2010 [Internet]. Geneva: WHO; 2010 p. 1-105.
Available from:
http://www.who.int/hiv/pub/mtct/antiretroviral
2010/en/ (accessed 20 October 2015).
13) Berheto TM, Haile DB, Mohammed S.
Predictors of loss to follow-up in patients
living with HIV/AIDS after initiation of
antiretroviral therapy. North Am J Med Sci.
2014 Sep; 6(9):453-9.
14) Clouse K, Pettifor A, Shearer K, Maskew M,
Bassett J, Larson B et al. Loss to follow-up
before and after delivery among women testing
HIV positive during pregnancy in
Johannesburg, South Africa. TM&IH. 2013
Apr; 18(4):451-60.
15) Meloni ST, Chang C, Chaplin B, Rawizza H,
Jolayemi O et al. Time dependant predictors of
loss to follow-up in a large HIV treatment
cohort in Nigeria. OFID. 2014 Jul 16; 1(2):1 –
11.
16) Bhagwanjee A, Govender K, Akintola O,
Petersen I, George G, Johnstone L, Naidoo K.
Patterns of disclosure and antiretroviral
treatment adherence in a South African mining
workplace programme and implications for
HIV prevention. Afr. J. AIDS Res. 2011 Dec 
15; 10(1): 357-68. 
17) Kunutsor S, Walley J, Katabira E, Muchuro S,
Balidawa H, Namagala E, Ikoona E. Improving
clinic attendance and adherence to
antiretroviral therapy through a treatment
supporter intervention in Uganda: A
randomized controlled trial. AIDS Behav. 2011
Nov; 15(8):1795-1802.
18) Makin JD, Forsyth BWC, Visser MJ, Sikkema
KJ, Neufeld S, Jeffery B. Factors affecting
disclosure in South African HIV positive
pregnant women. AIDS Patient Care STDS.
2008; 22(11):907-16.
19) Dzangare J, Takarinda KC, Harries AD,
Tayler-Smith K, Mhangara M, Apollo TM.
HIV testing uptake and retention in care of
HIV-infected pregnant and breastfeeding
women initiated on ‘Option B+’ in rural
Zimbabwe. Trop Med Int Health. 2016 Feb;
21(2):202-9.
20) Mitiku I, Arefayne M, Mesfin Y, Gizaw M.
Factors associated with loss to follow-up
among women in ‘Option B+’ PMTCT
programme in northeast Ethiopia: a
retrospective cohort study. J Int AIDS Soc.
2016 Mar 21; 19(20662):1-8.
20)21) Schmidt CO, Kohlmann T. When to use the
odds ratio or relative risk? Int J Public Health.




















Author Guidelines  
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 
INFORMATION PRIOR TO SUBMISSION (available from: 
http://www.jiasociety.org/index.php/jias/about/submissions) 
Aims and scope The JIAS welcomes submissions on HIV-related topics from across all scientific disciplines, 
including but not limited to:  
 Basic and biomedical sciences
 Behavioural sciences and epidemiology
 Clinical sciences
 Health economics and health policy
 Operations research and implementation sciences
 Social sciences and humanities, including political sciences and media
The JIAS places high priority on submissions from operational research and implementation science as 
publication of such material can provide valuable information on various algorithms for monitoring and 
providing support for comprehensive, yet affordable and sustainable treatment, prevention and care 
programmes in different contexts. Submission of HIV research carried out in low- and middle-income countries is 
strongly encouraged. The JIAS accepts submissions in the categories of Research, Short Report, Review, Debate, 
Commentary and Letter to the Editor.  
Ethical policies 
The JIAS is a member of the Committee on Publication Ethics (COPE) and endorses the World Association of 
Medical Editors' (WAME's) Policy Statement on Geopolitical Intrusion on Editorial Decisions. All submitted 
manuscripts are scanned for plagiarism and may be rejected if significant overlap with other published material 
is detected. Work presented in submitted manuscripts may not have been previously published; nor may the 
same manuscript be submitted for consideration to another journal simultaneously. Any misconduct by authors 
in reporting their data, for example, falsification, will lead to rejection of their manuscript and other 
consequences decided on by the Editors. Please see COPE and International Committee of Medical Journal 
Editors (ICMJE) for further information on ethical issues in publishing.  
Authorship 
 It is understood that all authors listed on submitted manuscripts have read and agreed to its content, and meet 
the authorship requirements as detailed by ICMJE here. In brief, contributors can be listed as authors if they:  
1) have made substantial contributions to conception and design, or acquisition of data, or analysis and
interpretation of data; AND
2) have been involved in drafting the manuscript or revising it critically for important intellectual content; AND
3) have given final approval of the version to be published. Each author should have participated sufficiently in
the work to take public responsibility for appropriate portions of the content. Acquisition of funding, collection
of data, or general supervision of the research group, alone, does not justify authorship. All contributors who do
not meet the criteria for authorship should be listed in the Acknowledgements section. Examples of those who
might be acknowledged include a person who provided purely technical help or writing assistance, or a head of
department, who provided only general support.
Ethical approval 
Experimental research described in the manuscript must have been performed with the approval of an 
appropriate ethics review board. Research carried out on humans must be in compliance with the Helsinki 
Declaration, and any experimental research on animals must have followed internationally recognized 
guidelines. A statement on the ethical aspects, including the consent procedure followed, must be included in 
the Methods section of the manuscript. The Editors may reject manuscripts where the research has not been 
carried out within an ethical framework. For all articles that include information or photographs relating to 
individuals, written and signed consent from each patient to publish must also be made available if requested by 
the Editors. Confidentiality of study participants must be ensured at all stages of research and reporting.  
Competing interests 
Authors are required to submit a statement on competing interests, which exist when personal or financial 
relationships with persons or organizations may influence the interpretation of the data or how the author's 
work is presented. For details, see ICMJE's policy on competing interests here. In brief, all financial competing 
interests must be disclosed in this statement (reimbursements, fees, funding, salary payments from or 
ownership of any stocks or shares in an organization that may in any way gain or lose financially from the 
publication of the manuscript, either now or in the future, or applications for patents relating to the content of 
the manuscript), as well as non-financial competing interests (such as political, personal, religious, ideological, 
academic and/or intellectual interests) that are related to the work submitted. The competing interest 
statement should be included in the manuscript and will be published in the final article. If no competing 
interests exist, please state in this section, "The author declare that they have (or The author declares that 
he/she has) no competing interests."  
Copyright and libel 
Legal responsibility to ensure that no material is published that infringes copyright or that includes libellous or 
defamatory content lies with the Journal of the International AIDS Society's publisher, the International AIDS 
Society. If a manuscript is judged by the journal Editors to include potentially libellous content, authors will be 
requested to adjust wording as necessary.  
Commercial writers and editors 
The involvement of scientific (medical) writers or anyone else who assisted with the preparation of the 
manuscript content should be acknowledged, along with their source of funding, as described in the European 
Medical Writers Association (EMWA) guidelines on the role of medical writers in developing peer-reviewed 
publications.  
MANUSCRIPT PREPARATION 
File formats  
Accepted files formats are OpenOffice, Microsoft Word, RTF or WordPerfect; in addition, a PDF copy of the 
manuscript needs to be prepared. Tables and figures should be inserted in the main text. Additional files, such as 
supporting information or large datasets, can be submitted in any file format and should be uploaded as a 
separate file. Footnotes are not allowed.  
Style and language 
Use line spacing of 1.5 and an easily readable font, for example, Times New Roman, size 12. Do not use 
underlining, but use of bold and italics is acceptable. Set the text unjustified to the left and use portrait page 
setup. Your manuscript must contain line numbers to facilitate editors' and reviewers' comments. All 
submissions must be in UK English (International) and UN-accepted terminology should be followed. No 
capitalization should be used except for grammatically correct use, official names and titles, and abbreviations. 
Acronyms should be used sparingly, and not in headings or in the Abstract. Only commonly known acronyms 
may be used, and they should be spelt out at first use followed by the abbreviation in brackets. SI units should 
be used, with litre and molar being permitted.  
Title page  
On the title page, you should mention the title of the manuscript, list all authors' names in full, and list any study 
groups if applicable. Each authors' affiliation should be numbered in superscript consecutively and listed 
underneath, including department, institution, city and country. The corresponding author should be marked 
with the symbol § in superscript and full contact details should be provided, including a telephone number with 
country code. Authors who have contributed equally to the work should be marked with the symbol * in 
superscript. Deceased authors should be marked with the symbol ^ in superscript. The email addresses of all 
authors should be listed by their initials. A list of six to eight keywords should be provided, preferably alternate 
words to those found in the abstract in order to improve search hits for the article in repositories.  
Abstract  
The Abstract should not exceed 350 words and should be structured according to the headings of the selected 
article category (see below), excluding the heading, Discussion for Research articles. Avoid using abbreviations 
and do not cite references in the Abstract. If you are reporting results from a controlled health care intervention, 
please include your trial registry, together with your unique identifying number at the end of the Abstract. For 
randomized controlled trials, follow the CONSORT extension for abstracts.  
Main text  
More information on the different article categories is provided below, including specific section headings and 
word limits. Information on the different sections in the manuscript is further detailed below, as well.  
Article categories  
Research - full reports of data from original research studies Headings: Introduction, Methods, Results, 
Discussion, Conclusions.  
Word limit: 3500 words  
Numbers of figures and tables: Unlimited  
Additional files: Yes Manuscript template  
Article sections  
Introduction The Introduction section should introduce the topic to readers without specialist knowledge in that 
area and must clearly outline the current state of knowledge in this field, the motivation and the aim of the 
study or the article.  
Methods The Methods section should include all information necessary to repeat the study, in particular, the 
study design, how data was collected and analyzed, clarifying the choice of methods that were made. If 
applicable, you should describe the setting of the study, the dates the study were conducted, and the sample or 
participants, as well as necessary power calculations and materials, including statistical packages, used. 
Interventions and programmes should be described in detail. Generic names for drugs or any molecules should 
be used. All studies involving humans or animals require a statement on ethical approval, and for the former, the 
consent procedure that was followed. Please include the names of the ethics review board(s) that approved the 
study. If the research study was specific to one sex/gender, the reasons for this should be clearly stated.  
Results This section should include only data and findings from the authors' study. Presentation of statistical 
results should mention confidence intervals and levels of significance where appropriate. Quotes from 
qualitative study participants of less than three lines should be quoted in the text using quotation marks. For 
quotes longer than three lines, place the quote in a separate, indented paragraph and introduce it with a colon. 
No quotation marks are needed in this case. Details of the participant can be added in round brackets following 
the quote, but should not contain identifiable information to ensure confidentiality. Clarifications within the 
quotation should be placed in square brackets. Submitting authors are strongly encouraged to include data 
disaggregated by sex (and, whenever possible, by race) and provide a comprehensive analysis of gender and 
racial differences. The authors should include the number and percentage of men, women and, if appropriate, 
transgender persons who participated in the research study. Anatomical and physiological differences between 
men and women (height, weight, body fat-to-muscle ratios, cell counts, hormonal cycles, etc.), as well as social 
and cultural variables (socio-economic, education, access to care, etc.), should be taken into consideration in the 
presentation of data and/or analysis of the results.  
Discussion In the Discussion section, you should discuss your main findings and place these within the context of 
the current body of knowledge in the field. Limitations of the study, for example, selection bias, can also be 
discussed, and should address how these influence the results and conclusions. If statistically significant 
differences were found between men and women or between different racial or cultural groups in the effects of 
the studied intervention, the implications, if any, for clinical and/or public health should be adequately 
discussed.  
Conclusions In your Conclusions section, state your key messages from the study and explain their importance 
and relevance, as well as implications. Future studies and recommendations can be included in this section. The 
conclusions drawn must be strictly based on the data provided.  
Figures Figures should be integrated into the text at the appropriate place. Figures should be cropped as closely 
as possible and have the header: "Figure 1. Title of figure". All figures need to be cited in the text in consecutive 
order. Legends should be provided underneath the figures, listing any abbreviations or meanings of symbols 
used. If several figures are included, please ensure that symbols are used consistently. Sufficient information 
needs to be provided for the figure to stand alone, including labels of axes. Please ensure that figures are legible 
in black and white print and also compatible with colour blindness. If figures are copied or adapted from another 
source, authors must seek permission prior to publication and these should be clearly cited as such. If the 
complete figure spans more than one page, authors should upload the figure as an additional file instead. High-
resolution illustrations are recommended for optimal viewing performance in the final article.  
Tables Tables must be created within the word file in the correct place and should have the header: "Table 1. 
Title of table". All tables should be cited in the text in consecutive order. The tables should not contain colour or 
shading, and no vertical, visible lines. A legend can be provided underneath the title, listing any abbreviations or 
meanings of symbols used. If several tables are included, please ensure that symbols are used consistently. If 
tables are copied or adapted from another source, permission must be sought by the authors prior to 
publication and these should be clearly cited as such. If a table spans more than one page, authors may want to 
consider uploading the table as an additional file instead.  
References All external sources of information should be referenced within the text, the tables and figures, using 
consecutive numbering in square brackets, e.g. [1], [3-5], [3,4]. The references should be up to date and 
adequately reflect the current state of knowledge in the field. Citation bias, for example, by country or point of 
view must be avoided. Numbers of references are unlimited for all article categories and should be formatted in 
standard Vancouver style; see Sample references from ICMJE. Unpublished observations, personal 
communications and manuscripts currently under consideration should be cited in the text in round brackets 
and not in the reference list. 
Data Collection Tool 

Letters to Facility Managers 

Consent Forms Facility Managers 

Human Research Ethics Approval Letter 
